← All trials
NCT04814004
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 19, 2021
- Primary completion
- Apr 1, 2023
- Completion date
- Apr 1, 2024
- First posted
- Mar 24, 2021
- Last posted
- Mar 29, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xuzhou Medical UniversityLead sponsor
- Zhejiang UniversityCollaborator
- Xuzhou Medical UniversityStudy chair
- Xuzhou Medical UniversitySponsor investigator
- Xuzhou Medical UniversityStudy director
- The First People's Hospital of ChangzhouCollaborator
- Nantong UniversityCollaborator
- Jiangsu UniversityCollaborator
- Huai'an First People's HospitalCollaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.